Arrowhead Pharmaceuticals Inc. (ARWR) announced Monday morning that it has completed enrollment of a Phase 1 clinical study of ARO-AAT. It is a potential treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
from RTT - Before the Bell https://ift.tt/2JSmBP3
via IFTTT
No comments:
Post a Comment